Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina

Indication
Cystic Fibrosis

Other upcoming events for VRTX

Patent ExpiryPatent/Exclusivity Expiry: APLENZIN
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subj
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subj
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Iv

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina — VRTX Phase 3 Readout | BioSniper